Analgesia Clinical Trials – What you should know but probably don’t

Get instant access

The hard truth: only 0.7% of new pain drugs progress from phase 1 clinical trials to US Food and Drug Administration approval. Analgesia clinical research is highly unique and nuanced.

In this webinar, Todd Bertoch, MD, Principal Investigator and CEO of CenExel JBR, provides insights on how to navigate the complexity of pain research to increase the likelihood of successful outcomes.